Sofosbuvir/ledipasvir produces early cure (SVR12) for 100% of HIV/HCV coinfected patients
Cinnamon Girl said
Apr 14, 2014
Treatment for 12 weeks with a coformulation of sofosbuvir and ledipasvir led to sustained response for all HIV/HCV coinfected patients with genotype 1 hepatitis C followed for 12 weeks post-treatment, according to interim findings from the ERADICATE study presented at the 49th EASL International Liver Congress in London.
Anu Osinusi from the U.S. National Institute of Allergy and Infectious Diseases and colleagues tested a once-daily fixed-dose combination pill containing the recently approved HCV polymerase inhibitor sofosbuvir (Sovaldi) plus the NS5A inhibitor ledipasvir (400/90mg) in patients coinfected with HIV and hepatitis C.
Historically, HIV/HCV coinfected people have not responded as well to interferon-based therapy as HIV-negative people with HCV alone, but recent data suggest that interferon-free direct-acting antiviral regimens may be equally effective in people with HIV. The Photon - 1 study testing sofosbuvir plus ribavirin found that coinfected people had sustained virological response rates at 12 weeks post-treatment (SVR12) similar to those previously seen in HCV monoinfected patients.
Treatment for 12 weeks with a coformulation of sofosbuvir and ledipasvir led to sustained response for all HIV/HCV coinfected patients with genotype 1 hepatitis C followed for 12 weeks post-treatment, according to interim findings from the ERADICATE study presented at the 49th EASL International Liver Congress in London.
Anu Osinusi from the U.S. National Institute of Allergy and Infectious Diseases and colleagues tested a once-daily fixed-dose combination pill containing the recently approved HCV polymerase inhibitor sofosbuvir (Sovaldi) plus the NS5A inhibitor ledipasvir (400/90mg) in patients coinfected with HIV and hepatitis C.
Historically, HIV/HCV coinfected people have not responded as well to interferon-based therapy as HIV-negative people with HCV alone, but recent data suggest that interferon-free direct-acting antiviral regimens may be equally effective in people with HIV. The Photon - 1 study testing sofosbuvir plus ribavirin found that coinfected people had sustained virological response rates at 12 weeks post-treatment (SVR12) similar to those previously seen in HCV monoinfected patients.
http://www.hepctrust.org.uk/News_Resources/news/2014/April/Sofosbuvir+ledipasvir+produces+early+cure+for+100+of+HIV+HCV+coinfected+patients